Company / SG&A Expense
Denali Therapeutics Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$136.6M
FY2025
5-year range
$46.5M / $136.6M
FY2021-FY2025
Trend
+29.5%
vs FY2024
Sector context
#98 of 213
Health Care
What the data says
At $137M, Denali Therapeutics Inc.'s sg&a expense ranks #116 of 213 in the Health Care sector. SG&A Expense has increased for 7 consecutive years, from $12M in FY2018 to $137M in FY2025.
Based on SEC 10-K filings.
$137M in FY2025 with a 5-year CAGR of +33.4%.
Increased from $103M to $137M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +31.3%
- 5-Year CAGR
- +33.4%
- 10-Year CAGR
- -
Sector benchmark
#116 of 213 in Health CareTop 54% of 213This company $136.6M Sector average $722.3M
▼
-81.1% below sector average
Key checks
Key Insights
- Denali Therapeutics Inc.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +33.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 29.5% year-over-year.
- Ranks #98 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $136.6M | +29.5% |
| FY2024 | $105.4M | +2.0% |
| FY2023 | $103.4M | +71.3% |
| FY2022 | $60.3M | +29.8% |
| FY2021 | $46.5M | +43.7% |
| FY2020 | $32.3M | +106.3% |
| FY2019 | $15.7M | +33.7% |
| FY2018 | $11.7M | -25.2% |
| FY2017 | $15.7M | +33.7% |
| FY2016 | $11.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026